爱博医疗(688050) - 2024 Q3 - 季度财报

Revenue and Profit Growth - Revenue for the third quarter reached 389.55 million yuan, a year-on-year increase of 49.11%[2] - Net profit attributable to shareholders of the listed company was 109.55 million yuan, up 23.38% year-on-year[2] - Total operating revenue for the first three quarters of 2024 reached 1,075,267,105.77 RMB, a significant increase from 668,099,047.91 RMB in the same period of 2023[14] - Net profit attributable to the parent company's shareholders for the first three quarters of 2024 was 913,270,453.15 RMB, up from 647,181,036.71 RMB in the same period of 2023[13] - Total profit for the period was RMB 361.83 million, an increase from RMB 277.23 million in the previous period[15] - Net profit attributable to the parent company's shareholders was RMB 317.59 million, up from RMB 251.97 million[15] - Basic earnings per share (EPS) increased to RMB 1.68 from RMB 1.33[15] R&D and Operating Expenses - R&D investment for the quarter was 39.93 million yuan, accounting for 10.25% of revenue, a decrease of 2.11 percentage points year-on-year[2] - R&D expenses for the first three quarters of 2024 amounted to 77,654,725.68 RMB, up from 64,674,073.63 RMB in the same period of 2023[14] - Sales expenses for the first three quarters of 2024 were 150,875,501.68 RMB, compared to 126,933,548.78 RMB in the same period of 2023[14] - Operating costs for the first three quarters of 2024 were 720,300,574.45 RMB, compared to 402,850,711.88 RMB in the same period of 2023[14] Assets and Liabilities - Total assets as of the end of the reporting period were 3.41 billion yuan, an increase of 11.24% compared to the end of the previous year[3] - The company's equity attributable to shareholders of the listed company was 2.33 billion yuan, up 9.42% from the end of the previous year[3] - Total assets as of Q3 2024 were 3,406,015,585.20 RMB, an increase from 3,061,786,608.56 RMB in the previous year[12] - Fixed assets increased to 1,387,928,661.32 RMB in Q3 2024, up from 1,088,802,327.00 RMB in the previous year[12] - Long-term loans rose to 547,497,926.78 RMB in Q3 2024, compared to 258,532,806.61 RMB in the previous year[13] - Total liabilities as of Q3 2024 were 863,139,790.82 RMB, up from 705,851,951.24 RMB in the previous year[13] Cash Flow and Financial Activities - Operating cash flow for the first three quarters was 217.06 million yuan, a significant increase of 65.99% year-on-year[2] - Net cash flow from operating activities was RMB 217.06 million, up from RMB 130.77 million[17] - Net cash flow from investing activities was negative RMB 597.13 million, compared to positive RMB 125.10 million in the previous year[18] - Net cash flow from financing activities was positive RMB 114.50 million, compared to negative RMB 53.95 million[18] - Total cash and cash equivalents at the end of the period were RMB 266.23 million, down from RMB 552.00 million[18] - Cash received from sales of goods and services was RMB 1,006.01 million, compared to RMB 658.87 million in the same period last year[17] - Cash paid for the purchase of goods and services was RMB 290.48 million, up from RMB 154.35 million[17] - Cash paid for the construction of fixed assets, intangible assets, and other long-term assets was RMB 284.24 million, compared to RMB 182.60 million[17] Shareholder and Equity Information - The company's total share capital increased from 105,250,992 shares at the beginning of the period to 189,544,528 shares at the end of the period[11] - The largest shareholder, Jie Jiangbing, holds 24,490,410 shares, accounting for 12.92% of the total shares[8] - Beijing Bojian Hechuang Technology Co., Ltd. holds 10,926,407 shares, accounting for 5.76% of the total shares[8] - Bai Ying holds 10,662,746 shares, accounting for 5.63% of the total shares[8] Financial Position and Performance Metrics - The company's basic earnings per share for the quarter were 0.58 yuan, a 23.40% increase year-on-year[2] - Weighted average return on equity (ROE) for the quarter was 4.74%, an increase of 0.36 percentage points year-on-year[2] - The company's revenue growth was driven by sustained growth in surgical treatment and myopia control businesses, as well as rapid growth in vision care business[6] - Operating profit for the first three quarters of 2024 was 363,056,896.70 RMB, compared to 277,234,392.29 RMB in the same period of 2023[14] Asset and Liability Changes - The company's monetary funds decreased from 536,658,290.19 RMB to 271,078,313.67 RMB[11] - The company's accounts receivable increased from 212,818,441.20 RMB to 386,231,641.63 RMB[11] - The company's inventory increased from 181,350,575.21 RMB to 247,963,387.33 RMB[11] - The company's trading financial assets increased significantly from 20,122,739.73 RMB to 198,171,961.25 RMB[11] - The company's prepayments slightly increased from 29,422,681.29 RMB to 30,260,973.37 RMB[11] - The company's other receivables decreased from 6,033,624.30 RMB to 4,480,013.42 RMB[11] Government Subsidies and Non-Recurring Gains - Government subsidies received during the quarter amounted to 5.37 million yuan, contributing to non-recurring gains[4]